Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells.

An iterative parallel synthesis effort identified a PLD2 selective inhibitor, ML298 (PLD1 IC50 > 20000 nM, PLD2 IC50 = 355 nM) and a dual PLD1/2 inhibitor, ML299 (PLD1 IC50 = 6 nM, PLD2 IC50 = 20 nM). SAR studies revealed that a small structural change (incorporation of a methyl group) increased PLD1 activity within this classically PLD2-preferring core and that the effect was enantiospecific. Both probes decreased invasive migration in U87-MG glioblastoma cells.

[1]  Y. Akao,et al.  Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer , 2003, Journal of Molecular Medicine.

[2]  Sarah A. Scott,et al.  Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity. , 2009, Bioorganic & medicinal chemistry letters.

[3]  Y. Akao,et al.  Increased activity and intranuclear expression of phospholipase D2 in human renal cancer. , 2000, Biochemical and biophysical research communications.

[4]  G. Stoll,et al.  Impaired αIIbβ3 Integrin Activation and Shear-Dependent Thrombus Formation in Mice Lacking Phospholipase D1 , 2010, Science Signaling.

[5]  H. V. van Praag,et al.  The clinical significance of halopemide, a dopamine-blocker related to the butyrophenones. , 1984, Neuropsychobiology.

[6]  D. A. Foster.  Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. , 2009, Biochimica et biophysica acta.

[7]  Sarah A. Scott,et al.  Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. , 2009, Nature chemical biology.

[8]  Sarah A. Scott,et al.  Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity. , 2009, Bioorganic & medicinal chemistry letters.

[9]  O. Arancio,et al.  Phospholipase D2 Ablation Ameliorates Alzheimer's Disease-Linked Synaptic Dysfunction and Cognitive Deficits , 2010, The Journal of Neuroscience.

[10]  Arthur Christopoulos,et al.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders , 2009, Nature Reviews Drug Discovery.

[11]  D. Noh,et al.  Overexpression of phospholipase D1 in human breast cancer tissues. , 2000, Cancer letters.

[12]  Sarah A. Scott,et al.  Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor. , 2010, Journal of medicinal chemistry.

[13]  P Jeffrey Conn,et al.  "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology. , 2011, Biochemistry.

[14]  C. Lindsley,et al.  Phospholipase D: enzymology, functionality, and chemical modulation. , 2011, Chemical reviews.

[15]  H. Brown,et al.  Biochemical analysis of phospholipase D. , 2007, Methods in enzymology.

[16]  W. Boyar,et al.  Optimization of halopemide for phospholipase D2 inhibition. , 2007, Bioorganic & medicinal chemistry letters.